Pulmonx Stock

Pulmonx FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pulmonx (LUNG) as of Aug 11, 2026 is 60.92 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 58.49 % — a change of 4.16% (higher).

FCF Conversion

60.92 %

YoY

4.16%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pulmonx is 2026 60.92 % . FCF Conversion Rate (FCF/EBITDA) of Pulmonx was 2025 58.49 % . It decreases by 4.16% higher compared to the previous year.
Access this data via the Eulerpool API

Pulmonx Stock analysis

What does Pulmonx do? Pulmonx Corp is an innovative medical technology company based in the USA and Europe. The company specializes in the development of non-invasive solutions for the treatment of lung diseases. Pulmonx was founded in 1997 and has since introduced numerous groundbreaking technologies to the market that improve the quality of life for patients with chronic lung diseases. Pulmonx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulmonx stock

FCF Conversion Rate (FCF/EBITDA) of Pulmonx is 60.92 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Pulmonx changed from 58.49 % to 60.92 %, representing a 4.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pulmonx since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pulmonx with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Pulmonx

All Key Metrics — Pulmonx